Background Locally advanced pancreatic cancer (LAPC) remains a challenge for current treatments. Local destructive therapies, such as irreversible electroporation (IRE) and radiofrequency ablation (RFA), were used more and more frequently in the treatment of LAPC. Objective This study aimed to compare the efficacy of IRE with RFA in patients with LAPC. Methods From August 2015 to August 2017, 58 LAPC patients after IRE or RFA therapy, which was performed through open approach, were retrospectively reviewed. The survival outcomes after IRE (36 patients) and RFA (18 patients) were compared after propensity score matching (PSM) analysis. Results Before PSM analysis, IRE after the induction chemotherapy resulted in significant higher overall survival (OS) rates and progression‐free survival (PFS) rates to RFA (2‐year OS, 53.5% vs 30.8%, P = .013; 2‐year PFS, 28.4% vs 12.1%, P = .043). After PSM analysis, compared with RFA, the survival benefit of IRE was even more obvious, (2‐year OS, 53.5% vs 27.0%, P = .010; 2‐year PFS, 28.4% vs 6.4%, P = .018). For patients with tumor larger than 4 cm, IRE resulted in comparable OS and PFS between RFA and IRE while IRE also achieved better long‐term OS to RFA for those with tumor smaller than 4 cm. Multivariate analysis illustrated that IRE was a favorable prognostic factor in terms of OS and PFS in patients with LAPC. Conclusions IRE after induction chemotherapy is superior to RFA after induction chemotherapy for treating LAPC patients while these two therapies have comparable efficacy for tumors which were larger than 4 cm., Locally advanced pancreatic cancer (LAPC) is a devastating disease while the standard chemotherapy remains an unmet need in the management of LAPC. Only a multidisciplinary approach can be effective in obtaining both a local tumor reduction and a systemic control of disease. Local destructive therapies were important components of the multidisciplinary treatment. Radiofrequency ablation (RFA) and irreversible electroporation (IRE) have been proposed as new treatment options in the multimodal treatment of the LAPC. Until recently, there is a lack of studies comparing treatment effects between IRE and RFA. Therefore, we aimed to investigate the effect of IRE versus RFA after the induction chemotherapy on long‐term OS and progression‐free survival (PFS) in patents with LAPC. It was the first time to show that IRE resulted in better OS and PFS than RFA after the induction chemotherapy in patients with LAPC and should be considered as the first‐line ablation modality. A new ablative method, RFA ablation followed by tumor margin accentuation by IRE, is also considerable.